BCS Symposium 2026: Dr. Alison Muir

Skip to main content

Obstructive
HCM

About obstructive HCM

Identifying patients

Treatment landscape

Patient profiles

Symptoms and Diagnosis

Echocardiography and obstructive hypertrophic cardiomyopathy

About
Mavacamten

NICE recommendations

Clinical
Studies

EXPLORER-HCM primary endpoint

EXPLORER-HCM secondary endpoints

EXPLORER-HCM exploratory endpoints

VALOR-HCM primary endpoint

EXPLORER-LTE durable efficacy

Important information

Drug interactions

Dosing and initiation

Maintenance and interruption

Special populations

British Cardiovascular Society (BCS) Symposium 2026

BCS Symposium 2026: Dr. Alison Muir

Identifying the right Mavacamten patient and why — Speaker: Dr. Alison Muir

3500-GB-2600201 | September 2026

References

Prescribing Information can be accessed using the link at the top of the page.

Adverse events should be reported. Reporting forms and information can be found at: UK - http://www.mhra.gov.uk/yellowcard, or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Bristol-Myers Squibb via medical.information@bms.com or 0800 731 1736 (UK).

Legal Notice | Privacy Policy | Cookie Preferences

© 2026 Bristol-Myers Squibb Company.

3500-GB-2600057 | March 2026